Abstract
Eicosapentaenoic acid (EPA) ethyl ester (1.8 g/d) was administered to 16 diabetic patients (5 insulin-dependent and 11 noninsulin-dependent diabetics) for 6 mon. EPA in total plasma fatty acids increased from 4.0±2.4 mol% (mean±SD) to 7.5±3.1 mol% (p<0.001). Albumin excretion, measured with spot urine, was significantly reduced from 65 to 36 mg/g creatinine (geometric means, p<0.001). Fasting blood sugar levels, glycohemoglobin, body weight and blood pressure did not change significantly during the study. There were also no significant changes in serum levels of creatinine, urea nitrogen, total cholesterol and triglycerides. Although no overt hemorrhage was observed in the patients, hematocrit was reduced from 42.6±2.8% to 41.0±3.9% (p<0.02). Ten other similar diabetic patients (4 insulin-dependent and 6 non-insulin-dependent diabetics) were followed as a reference group, not concomitantly, for 6 mon with neither EPA ethyl ester nor placebo. The parameters mentioned above were not changed significantly in this group during 6 mon. EPA administration might retard the appearance of overt diabetic nephropathy.
Similar content being viewed by others
Abbreviations
- DM:
-
diabetes mellitus
- EPA:
-
eicosapentaenoic acid
- HbA1c :
-
glycosylated hemoglobin A1c
- IDDM:
-
insulin-dependent diabetes mellitus
- NIDDM:
-
noninsulin-dependent diabetes mellitus
References
Christiansen, J.S., Andersen, A.R., Andersen, J.K., and Deckert, T. (1985)Diabetic Nephropathy 4, 104–106.
Feldt-Rasmussen, B., Mathiesen, E., and Deckert, T. (1986)Lancet 2, 1300–1304.
Dahl-Jørgensen, K., Hanssen, K.F., Kierulf, P., Bjøro, T., Sandvik, L., and Aagenaese, Ø. (1988)Acta Endocrinol. (Copenh) 117, 19–25.
Feldt-Rasmussen, B., Mathiesen, E.R., Hegedüs, L., and Deckert, T. (1986)N. Engl. J. Med. 314, 665–670.
Christensen, C.K., and Mogensen, C.E. (1985)Diabetic Nephropathy 4, 34–40.
Parving, H-H., Andersen, A.R., Smidt, U.M., Hommel, E., Mathiesen, E.R., and Svendsen, P.A.A. (1987)Br. Med. J. 294, 1443–1447.
Hommel, E., Parving, H-H., Mathiesen, E., Edsberg, B., Damkjaer Nielsen, D., and Giese, J. (1986)Br. Med. J. 293, 467–470.
Bending, J.J., Dodds, R., Keen, H., and Viberti, G.C. (1986)Diabetologia 29, 516A.
Mogensen, C.E., and Osterby, R. (1987)Front. Diab. 8, 67–81.
Hamazaki, T., Hirai, A., Terano, T., Sajiki, J., Kondo, S., Fujita, T., Tamura, Y., and Kumagai, A. (1982)Prostaglandins 23, 557–567.
Kobayashi, S., Hamazaki, T., Hirai, A., Terano, T., Tamura, Y., Kanakubo, Y., Yoshida, S., Fujita, T., and Kumagai, A. (1985)Clin. Hemorheol. 5, 493–505.
Hamazaki, T., Nakazawa, R., Tateno, S., Shishido, H., Isoda, K., Hattori, Y., Yoshida, T., Fujita, T., Yano, S., and Kumagai, A. (1984)Kidney Int. 26, 81–84.
Prickett, J.D., Robinson, D.R., and Steinberg, A.D. (1981)J. Clin. Invest. 68, 556–559.
Barcelli, U.O., Miyata, J., Ito, Y., Gallon, L., Laskorzewski, P., Weiss, M., Hitzemann, R., and Pollak, V.E. (1986)Prostaglandins 32, 211–219.
Schaap, G.H., Bilo, H.J.G., Popp-Snijders, C., Oe, P.L., Mulder, C., and Donker, A.J.M. (1987)Life Sci. 41, 2759–2765.
Alexander, N.J., Smythe, N.L., and Jokinen, M.P. (1987)Am. J. Pathol. 127, 106–121.
Kelley, V.E., Ferretti, A., Izui, S., and Storm, T.B. (1985)J. Immunol. 134, 1914–1919.
Robinson, D.R., Prickett, J.D., Polisson, R., Steinberg, A.D., and Levine, L. (1985)Prostaglandins 30, 51–57.
Ito, Y., Barcelli, U.O., Yamashita, W., Weiss, M., Thompson, B., Kashyap, M., Deddens, J., and Pollak, V.E. (1987)Life Sci. 40, 2317–2323.
Elzinga, L., Kelley, V.E., Houghton, D.C., and Bennett, W.M. (1987)Transplantation 43, 271–274.
Papanikolaou, N. (1987)Prostaglandins Leukotrienes Med. 27, 129–149.
Hamazaki, T., Tateno, S., and Shishido, H. (1984)Lancet 1, 1017–1018.
Fujikawa, M., Yamazaki, K., Sawazaki, S., Taki, H., Kaneda, M., Urakaze, M., Hamazaki, T., Yano, S., and Fujita, T. (1989)Lipids 24, 765–768.
Siess, W., Roth, P., Scherer, B., Kurzmann, I., Böhlig, B., and Weber, P.C. (1980)Lancet 1, 441–444.
Lorenz, R., Spengler, U., Fischer, S., Duhm, J., and Weber, P.C. (1980)Circulation 67, 504–511.
Kamada, T., Yamashita, T., Baba, Y., Kai, M., Setoyama, S., Chuman, Y., and Tsuji, S. (1986)Diabetes 35, 604–611.
Terano, T., Hirai, A., Hamazaki, T., Kobayashi, S., Fujita, T., Tamura, Y., and Kumagai, A. (1983)Atherosclerosis 46, 321–331.
Urakaze, M., Hamazaki, T., Kashiwabara, H., Omori, K., Fischer, S., Yano, S., and Kumagai, A. (1989)Nephron 53, 102–109.
Mortensen, J.Z., Schmidt, E.B., Nielsen, A.H., and Dyerberg, J. (1983)Thromb. Haemostas 50, 543–546.
Haines, A.P., Sanders, T.A.B., Imeson, J.D., Mahler, R.F., Martin, J., Mistry, M., Vickers, M., and Wallace, P.G. (1986)Thrombosis Res. 43, 643–655.
Glauber, H., Wallace, P., Griver, K., and Brechtel, G. (1988)Ann. Intern. Med. 108, 663–668.
Author information
Authors and Affiliations
About this article
Cite this article
Hamazaki, T., Takazakura, E., Osawa, K. et al. Reduction in microalbuminuria in diabetics by eicosapentaenoic acid ethyl ester. Lipids 25, 541–545 (1990). https://doi.org/10.1007/BF02537161
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02537161